2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-169196
    D-687
    		Inhibitor
    D-687 is an inhibitor of Tau and Aβ. D-687 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties.
    D-687
  • HY-152031
    Glutaminyl Cyclase Inhibitor 5
    		Inhibitor
    Glutaminyl Cyclase Inhibitor 5 (Compound 71) is a potent and selective human glutaminyl cyclase (hQC) inhibitor with an IC50 of 3.2 nM.
    Glutaminyl Cyclase Inhibitor 5
  • HY-N0044R
    Ginsenoside Re (Standard)
    		Inhibitor
    Ginsenoside Re (Standard) is the analytical standard of Ginsenoside Re. This product is intended for research and analytical applications. Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
    Ginsenoside Re (Standard)
  • HY-152111
    AChE/MAO-B-IN-3
    		Inhibitor
    AChE/MAO-B-IN-3 (Compound D30) is a dual AChE and MAO-B inhibitor with IC50s of 0.0257 μM and 0.0456 μM against human AChE and MAO-B, respectively. AChE/MAO-B-IN-3 can be used for the research of Alzheimer’s disease.
    AChE/MAO-B-IN-3
  • HY-B0104S2
    Glimepiride-d8
    		Inhibitor
    Glimepiride-d8 (Glimperide-d8; HOE-490-d8) is deuterium-labeled Glimepiride (HY-B0104).
    Glimepiride-d<sub>8</sub>
  • HY-169197
    D-688
    		Inhibitor
    D-688 is an inhibitor of Tau and Aβ. D-688 can reverse Aβ1–42-induced toxicity in SH-SH5Y cells and has significant neuroprotective properties. D-688 can improve the survival rate of Drosophila melanogaster expressing the human tau protein isoform (2N4R).
    D-688
  • HY-146347
    MAO-B-IN-10
    		Inhibitor
    MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated MAO-B (monoamine oxidase-B) inhibitor, with IC50 of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research.
    MAO-B-IN-10
  • HY-146251
    BuChE-IN-6
    		Inhibitor
    BuChE-IN-6 (compound 1b) is a potent and selective BuChE (butyrylcholinesterase) inhibitor, with IC50 values of 0.46 and 0.51 μM for eqBuChE and hBuChE, respectively. BuChE-IN-6 also inhibits Aβ42 self-aggregation.
    BuChE-IN-6
  • HY-P990595
    GSK-933776
    		Inhibitor
    GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    GSK-933776
  • HY-179459
    SJ-300
    		Inhibitor
    SJ-300 is a potent and selective, orally active and brain-penetrat DKK3-LRP1 interaction inhibitor. SJ-300 restores Aβ clearance in AD models. SJ 300 binds to mLRPIV with a Kd of 7.9 μM, inhibits the DKK3 mLRPIV complex with an IC50 of 3.2 μM, and does not disrupt the binding of Aβ to LRP1. SJ 300 rescues cognitive function and ameliorates neuropathology (Aβ plaque reduction ≈ 73.3 %) in vivo. SJ 300 can be employed for research in Alzheimer’s disease.
    SJ-300
  • HY-P2792
    Beauveriolide III
    		Inhibitor 99.9%
    Beauveriolide III is an inhibitor of lipid droplet formation in mouse macrophages.
    Beauveriolide III
  • HY-181041
    Multitarget AD-IN-5
    		Inhibitor
    Multitarget AD-IN-5 (Compound 20), 9-Aminoacridine (HY-B1422) derivative, is a neuroprotective agent. Multitarget AD-IN-5 shows IC50 values of 0.614, 0.448, 3.73 and 1.55 μM for hAChE, hBChE, hMAO-A and hMAO-B. Multitarget AD-IN-5 can reduce length and diameter of Aβ42 fibers, and decrease the number of fibers per unit area. Multitarget AD-IN-5 can be used for research of Alzheimer's disease.
    Multitarget AD-IN-5
  • HY-149211
    AChE/BChE-IN-12
    		Inhibitor
    AChE/BChE-IN-12 (compound 10b), a 3,5-dimethoxy analogue, is a potent AChE, BChE, and β-secretase-1 (BACE-1) inhibitor, with IC50 values of 2.57, 3.26, and 10.65 μM, respectively. AChE/BChE-IN-12 crosses the blood-brain barrier via passive diffusion and inhibits the self-aggregation of amyloid-β monomers. AChE/BChE-IN-12 can be used for Alzheimer’s disease (AD) research.
    AChE/BChE-IN-12
  • HY-173282
    Aβ aggregation-IN-2
    		Inhibitor
    Aβ aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease.
    Aβ aggregation-IN-2
  • HY-161512
    hAChE/hBACE-1-IN-4
    		Inhibitor
    hAChE/hBACE-1-IN-4 (compound AK-2) is a quinazoline derivative. hAChE/hBACE-1-IN-4 shows significant inhibitory activity against hAChE and hBACE-1 enzymes (hAChE, IC50=0.283 μM; hBACE-1, IC50=0.231 μM). hAChE/hBACE-1-IN-4 has the potential to inhibit Aβ aggregation. hAChE/hBACE-1-IN-4 has non-neurotoxicity , blood-brain barrier permeability and oral activity. hAChE/hBACE-1-IN-4 can be used in Alzheimer's disease research.
    hAChE/hBACE-1-IN-4
  • HY-146619
    RAGE/SERT-IN-1
    		Inhibitor
    RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression.
    RAGE/SERT-IN-1
  • HY-B0949R
    Protriptyline hydrochloride (Standard)
    		Inhibitor
    Protriptyline hydrochloride (Standard) is the analytical standard of Protriptyline hydrochloride (HY-B0949). This product is intended for research and analytical applications. Protriptyline hydrochloride is a potent tricyclic antidepressant (TCA). Protriptyline hydrochloride inhibits AChE activity with an IC50 value of 0.06 mM and inhibits Aβ self-assembly. Protriptyline hydrochloride can be used for the study of depression and Alzheimers disease.
    Protriptyline hydrochloride (Standard)
  • HY-P10578
    SEN 304
    		Inhibitor
    SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease.
    SEN 304
  • HY-112270
    Glutaminyl Cyclase Inhibitor 2
    		Inhibitor
    Glutaminyl Cyclase Inhibitor 2 is a glutaminyl cyclase inhibitor with an IC50 of 1.23 μM.
    Glutaminyl Cyclase Inhibitor 2
  • HY-W098905
    GSK3β-IN-3
    		Inhibitor
    GSK3β-IN-3 is an ATP-competitive GSK-3β inhibitor (IC50 = 0.90 μM). GSK3β-IN-3 can reduce the phosphorylation level of tau protein in the BR5706 strain and reduce the deposition of Aβ aggregates in the CL2006 strain, and can be used to research Alzheimer's disease (AD).
    GSK3β-IN-3
Cat. No. Product Name / Synonyms Application Reactivity